Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

deva holding a.s., turkey - imatinib mesilate - tablet - 100 mg

Kenya - English - Pharmacy and Poisons Board

deva holdings a.s. p.o box 27080 -00100 - cefuroxime sodium - powder for solution for injection - 750mg - beta-lactamantibacterials: second-generation

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenindione -

Australia - English - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: xanthan gum; hypromellose; silicon dioxide; saccharin sodium; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; flavour - amoklavin duo 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoklavin duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoklavin duo 400/57, should not require the addition of another antibiotic due to the amoxicillin content of amoklavin duo 400/57.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - nystatin 100000 iu/ml (micronised);   - oral drops - 100000 iu/ml - active: nystatin 100000 iu/ml (micronised)   excipient: carmellose sodium cherry flavour imitation 15239 cinnamaldehyde dibasic sodium phosphate ethanol glycerol hydrochloric acid methyl hydroxybenzoate peppermint oil propyl hydroxybenzoate purified water sucrose - treatment of infections of the oral cavity caused by candida albicans

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 10mg - capsule - 10 mg - active: lenalidomide 10mg excipient: croscarmellose sodium gelatin indigo carmine iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 15mg - capsule - 15 mg - active: lenalidomide 15mg excipient: croscarmellose sodium gelatin indigo carmine lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: croscarmellose sodium gelatin indigo carmine iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 25mg - capsule - 25 mg - active: lenalidomide 25mg excipient: croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.